Extended MHB018A treatment for thyroid eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, open-label extension gives MHB018A injections to adults with active or chronic moderate-to-severe TED who completed the 24-week double-blind period of the preceding phase 3 trials. Eligible participants are proptosis non-responders at Week 24 or meet retreatment criteria for relapse and are enrolled within 28 days of their previous study visit. The primary outcome is change in proptosis from the most recent measurement prior to the first dose in this extension, with safety and tolerability monitored throughout. Subjects must not require immediate ophthalmic surgery or have planned corrective surgery or orbital radiotherapy during participation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subjects voluntarily participating in the study and signing the informed consent form;
2. Aged 18-75 years (inclusive), of any gender;
3. Completed the 24-week double-blind treatment period in either the MHB018A-P-301 or MHB018A-P-302 study, and within 28 days after Week 24 visit of the previous study when enrolled in this OLE study (does not apply to subjects who meet the relapse criteria during the safety follow-up period).
4. Proptosis non-responder at Week 24 visit in the double-blind treatment period of either the MHB018A-P-301 or MHB018A-P-302 study (defined as a \<2 mm reduction from baseline in the study eye, or a ≥2 mm reduction in the study eye accompanied by a ≥2 mm worsening from baseline in proptosis of the fellow eye), and/or who meet the retreatment criteria for relapse during the safety follow-up period.
5. Does not require immediate surgical ophthalmological intervention, and no corrective surgery/orbital radiotherapy is planned during the study.
6. Diabetic subjects must have well-controlled stable disease.
7. Sufficient bone marrow and organ function.
8. Eligible subjects of childbearing potential (male and female) must agree to use reliable contraceptive methods; female subjects of childbearing potential must have a negative blood pregnancy test within 7 days before the first use of the study drug and must not be breastfeeding.
9. Subject is willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.

   \-

Exclusion Criteria:

1. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision within the last 6 months of two lines of Snellen chart, new visual field defect or color defect secondary to optic nerve involvement.
2. Corneal decompensation unresponsive to medical management.
3. Free thyroxine (FT4) and free triiodothyronine (FT3) levels \<50% above or below the normal reference range at screening.
4. Received any treatment for TED, intravenous corticosteroids, immunosuppressive agents, investigational drug from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study.
5. Identified pre-existing ophthalmic disease that would preclude study participation or complicate interpretation of the study results.
6. Acute cardiovascular disease history or treatment within 6 months before the first dose from the last visit of the MHB018A-P-301 or MHB018A-P-302 trial until participation in this study.
7. Presence of poorly controlled hypertension with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; Renal artery stenosis.
8. Pregnant or lactating women.
9. Tinnitus or other hearing impairment.
10. Poor compliance or severe systemic disease history or other reasons that make the subject unsuitable for participation in this clinical study.

    \-

Where it's running

• Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: CMO/ Senior Vice President of R&D
• Email: jwshi@minghuipharma.com
• Phone: 86 0571-86963293

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Linsitinib in moderate to severe Thyroid Eye Disease (TED)

  This study tests whether linsitinib can help people with moderate to severe TED associated with Graves' disease or Hashimoto's thyroiditis.

  Recruiting at 17 sites Phase 3 Sling Therapeutics, Inc. · Glendale, Arizona and 17 other locations · NCT07753603

• MHB018A injections for chronic moderate-to-severe thyroid eye disease

  This study tests whether MHB018A injections work better than a placebo for adults with chronic moderate-to-severe thyroid eye disease.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Coral Gables, Florida · NCT07622121

• Treating Active Thyroid Eye Disease with MHB018A vs placebo

  In people with active moderate-to-severe TED, this study tests whether an antibody called MHB018A can help reduce eye inflammation and swelling compared with a placebo.

  Recruiting Phase 3 Minghui Pharmaceutical (Hangzhou) Ltd · Coral Gables, Florida · NCT07622108

• Cizutamig in thyroid eye disease for adults

  This study tests how safe and potentially effective cizutamig is in adults with active thyroid eye disease.

  Recruiting at 14 sites Phase 1 Candid Therapeutics · Hefei, Anhui and 13 other locations · NCT07597200

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.